Drug Approval | September 28, 2024
FDA approves Bristol Myers Squibb’s Cobenfy
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol
LEO Pharma is developing delgocitinib cream for the treatment of moderate to severe chronic hand eczema, a hard-to-treat disease where there is a high unmet medical need for treatment
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
Subscribe To Our Newsletter & Stay Updated
